Press Release

D3 Bio Completes $62 Million Series A+

April 8, 2024

Shanghai – April 8, 2024 – Cooley advised D3 Bio, an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs, on the close of its $62 million Series A+ financing. The financing round was led by Medicxi, with participation from existing investors Matrix Partners China and WuXi AppTec’s Corporate Venture Fund.

Lawyers Christina Zhang, Andrew Harline and Lunga Su led the Cooley team advising D3 Bio.

Cooley has advised D3 Bio since its inception, including on its $200 million Series A in November 2020.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.